NCT05830097 2024-08-26
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Coherent Biopharma (Hefei) Co., Ltd.
Phase 1/2 Unknown
Clinical Trials
334 trialsNCT03275493 2024-05-28
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2 Unknown
NCT06308406 2024-04-11
A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Unknown
NCT04903873 2024-03-15
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
Eutilex
Phase 1/2 Unknown
NCT03975907 2024-03-12
Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
CARsgen Therapeutics Co., Ltd.
Phase 1/2 Unknown
NCT04601584 2024-03-06
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
AO GENERIUM
Phase 1/2 Unknown
NCT06237413 2024-03-06
A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Unknown
NCT04780217 2024-03-04
Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors
ImmVira Pharma Co. Ltd
Phase 1/2 Unknown
NCT04934514 2024-02-20
Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 1/2 Unknown
NCT05991518 2024-02-20
IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors
SUNHO（China）BioPharmaceutical CO., Ltd.
Phase 1/2 Unknown
NCT04984668 2024-02-09
A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors
Suzhou Kintor Pharmaceutical Inc,
Phase 1/2 Unknown
NCT05358379 2024-02-07
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Unknown
NCT04358393 2024-02-01
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT06237400 2024-02-01
A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2 Unknown
NCT05675605 2024-01-30
A Study of TY-1091 in Patients With Advanced Solid Tumors
TYK Medicines, Inc
Phase 1/2 Unknown
NCT05278975 2024-01-26
Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
RS Oncology LLC
Phase 1/2 Unknown
NCT04983810 2024-01-25
A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Unknown
NCT06223308 2024-01-25
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2 Unknown
NCT06223646 2024-01-25
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Phase 1/2 Unknown
NCT05186012 2024-01-23
APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT06218771 2024-01-23
A Study of TQB3454 Tablets in Patients With Blood Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Unknown
NCT04284228 2024-01-16
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT
NexImmune Inc.
Phase 1/2 Unknown
NCT05906524 2024-01-10
KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors
Shanghai Kanda Biotechnology Co., Ltd.
Phase 1/2 Unknown
NCT05705505 2023-12-12
Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
Traws Pharma, Inc.
Phase 1/2 Unknown
NCT03614858 2023-11-29
CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2 Unknown
NCT03896854 2023-11-29
CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2 Unknown
NCT05745740 2023-11-27
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
RemeGen Co., Ltd.
Phase 1/2 Unknown
NCT02557321 2023-11-21
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
Provectus Pharmaceuticals
Phase 1/2 Unknown
NCT06126237 2023-11-13
A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
Keymed Biosciences Co.Ltd
Phase 1/2 Unknown
NCT05094804 2023-11-02
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
Phase 1/2 Unknown
NCT04097002 2023-10-31
First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients.
Orca Therapeutics B.V.
Phase 1/2 Unknown
NCT04942067 2023-10-25
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT04964518 2023-10-25
A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT06056323 2023-10-23
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2 Unknown
NCT06092268 2023-10-23
A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Unknown
NCT03382340 2023-09-28
IMX-110 in Patients With Advanced Solid Tumors
Immix Biopharma, Inc.
Phase 1/2 Unknown
NCT05728619 2023-09-28
HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 1/2 Unknown
NCT06055348 2023-09-26
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
Biocity Biopharmaceutics Co., Ltd.
Phase 1/2 Unknown
NCT05448820 2023-09-21
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
Tracon Pharmaceuticals Inc.
Phase 1/2 Unknown
NCT06041035 2023-09-18
A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Unknown
NCT06008366 2023-09-13
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT06008379 2023-09-13
A Study of 7MW3711 in Subjects With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Unknown
NCT06006104 2023-08-23
Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Unknown
NCT03887273 2023-08-21
Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis
Q Therapeutics, Inc.
Phase 1/2 Unknown
NCT05102292 2023-08-21
The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation
Shanghai Henlius Biotech
Phase 1/2 Unknown
NCT05102214 2023-08-08
HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase 1/2 Unknown
NCT05390528 2023-08-08
HLX301
Shanghai Henlius Biotech
Phase 1/2 Unknown
NCT05840835 2023-08-08
IMMINENT-01
Immix Biopharma, Inc.
Phase 1/2 Unknown
NCT05978401 2023-08-07
Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer
Guangzhou Gloria Biosciences Co., Ltd.
Phase 1/2 Unknown
NCT03867682 2023-08-04
Venetoclax and Lintuzumab-Ac225 in AML Patients
Actinium Pharmaceuticals
Phase 1/2 Unknown